Related references
Note: Only part of the references are listed.Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study
Tadao Akizawa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2020)
Oral roxadustat three times weekly in ESA-naive and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies
Tadao Akizawa et al.
THERAPEUTIC APHERESIS AND DIALYSIS (2020)
Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan
Tadao Akizawa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naive Chronic Kidney Disease Patients Not on Dialysis
Tadao Akizawa et al.
NEPHRON (2020)
Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Tadao Akizawa et al.
ADVANCES IN THERAPY (2019)
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
N. Chen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Hypoxia-Inducible Factor and Its Role in the Management of Anemia in Chronic Kidney Disease
Joshua M. Kaplan et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Prolyl Hydroxylase Inhibitors: A Breakthrough in the Therapy of Anemia Associated with Chronic Diseases
Amit A. Joharapurkar et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Physiology and pathophysiology of renal erythropoietin-producing cells
Hong-Mou Shih et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2018)
Therapeutic targeting of the HIF oxygen-sensing pathway: Lessons learned from clinical studies
Volker H. Haase
EXPERIMENTAL CELL RESEARCH (2017)
Hypoxia-inducible factor 1α activates insulin-induced gene 2 (Insig-2) transcription for degradation of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase in the liver
Seonghwan Hwang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China
Nan Chen et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2017)
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Francesco Locatelli et al.
AMERICAN JOURNAL OF NEPHROLOGY (2017)
Roxadustat (FG-4592): Correction of Anemia in Incident Dialysis Patients
Anatole Besarab et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients
Jiacong Luo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6-to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy Study
Robert Provenzano et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2016)
Macrophages and iron trafficking at the birth and death of red cells
Tamara Korolnek et al.
BLOOD (2015)
A randomized trial of intravenous and oral iron in chronic kidney disease
Rajiv Agarwal et al.
KIDNEY INTERNATIONAL (2015)
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
Anatole Besarab et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2015)
Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study
Rieko Eriguchi et al.
JOURNAL OF NEPHROLOGY (2015)
Comments on 'KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease'
Konrad M. Andrassy
KIDNEY INTERNATIONAL (2013)
Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Iain C. Macdougall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Mechanisms of Anemia in CKD
Jodie L. Babitt et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study Equations: Prevalence of and Risk Factors for Diabetes Mellitus in CKD in the Kidney Early Evaluation Program (KEEP)
Samy I. McFarlane et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2011)
Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease
Stephen L. Seliger et al.
KIDNEY INTERNATIONAL (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent et al.
LANCET (2011)
Cardiorenal Interaction: Appropriate Treatment of Cardiovascular Risk Factors to Improve Outcomes in Chronic Kidney Disease
Peter A. McCullough et al.
POSTGRADUATE MEDICINE (2010)
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
Marc A. Pfeffer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Hypoxia stimulates degradation of 3-hydroxy-3-methylglutaryl-coenzyme a reductase through accumulation of lanosterol and hypoxia-inducible factor-mediated induction of Insigs
Andrew D. Nguyen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia
JW Kim et al.
CELL METABOLISM (2006)
Share Paper
